Loading clinical trials...

MAAT For Young Adult Cancer Survivors | Clinical Trials | Clareo Health

COMPLETEDNA

MAAT For Young Adult Cancer Survivors

Modifying Memory and Attention Adaptation Training (MAAT) For Young Adult Childhood Cancer Survivors

NCT06150976•University of Pittsburgh

View on ClinicalTrials.gov

Summary

Detailed Description

The goal of this clinical trial is to pilot-test a modified version of telehealth-delivered Memory and Attention Adaption Training (MAAT) that is tailored to young adult childhood cancer survivors (ages 18-39; MAAT-YS) with cancer-related cognitive impairment (CRCI). MAAT-YS consists of 8 weekly visits (45-minutes in duration) and participants use a survivor workbook and complete homework between visits. This pilot trial will determine MAAT-YS feasibility, treatment satisfaction and size of effect in self-report and objective measures of neurocognitive function. Eligible participants will be 9 individuals who were diagnosed with non-central-nervous system (CNS) cancer (including leukemia/lymphoma without known CNS involvement) prior to the age of 18, are at least 1-year from completion of cancer treatment, including chemotherapy. Participants will complete online self-report measures of cognitive symptoms, quality of life, treatment satisfaction and a brief online neuropsychological test battery at baseline and post-MAAT-YS timepoints. If successful, further research is planned with a larger, multi-site randomized controlled trial of MAAT-YS.

Eligibility

Age

18 - 39 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adults aged 18-39
•2. Diagnosed prior to 18 years of age with non-CNS solid tumor or leukemia/lymphoma without known CNS involvement
•3. At least 1 year after completion of treatment including chemotherapy, cancer-free
•4. English fluent
•5. Memory or other cognitive problems attributed to cancer and/or cancer treatment
•6. Score of \<10 on the FACT-Cog Impact on Quality of Life Scale
•7. Willing to use telehealth with internet access
•8. Willing to provide informed consent to participation

Exclusion Criteria

•1. Severe non-cancer brain injury such as severe traumatic brain injury, stroke or toxic injury causing memory impairments;
•2. Currently meeting Diagnostic and Statistical Manual-5 (DSM-5) criteria for a severe psychiatric disorder, including substance abuse, mood, anxiety, or psychotic disorders, as assessed by the PRIME-MD;
•3. Scoring 3 or below on the 6-item cognitive screen designed to detect severe memory disorders;59
•4. Severe uncorrected sensory impairment (severe hearing or visual impairment).

Locations (3)

Indiana University School of Medicine

Indianapolis, Indiana, United States

University of Pittsburgh School of Medicine/UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

St. Jude Children's Research Hospital

Memphis, Tennessee, United States

Key Dates

Start Date

February 12, 2025

Primary Completion Date

September 5, 2025

Completion Date

September 5, 2025

Last Updated

January 12, 2026

Enrollment

ACTUAL participants

Conditions

Cancer

Interventions

MAAT-YS

BEHAVIORAL

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

NCT06066138

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part Sarcoma+8 more

View study

RECRUITINGPHASE2

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

NCT05198830

Lung AdenocarcinomaLung Large Cell Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MAAT For Young Adult Cancer Survivors

Inclusion Criteria

Exclusion Criteria

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial